Replying to @AbudBakri
Talking about epi pens, this is a great option as well. Same as an epi pen.
1
52
Don't trust our CoA. Check it.
Every batch on our CoA page opens its report on the testing lab's own website, not ours. Here's the 60-second check ↓
6 tests per batch: identity, mass, purity, sterility, endotoxins, heavy metals.
Research use only.
clearbatch.net/certificates-…
Quick review of why working with us is a no-brainer when it comes to research peptides and reagents sourcing.
2
273
Replying to @DrJesseMorse @billlight74
Agree on rolling the dice but our testing speaks for itself.
portal.ils-lab.com/verify/V6…
1
3
31
Replying to @JamesR0bby
For maximum potential weight loss: retatrutide currently appears strongest, with average losses approaching 28–30%, but it remains investigational and its long-term risk-benefit profile is still being established.
For a different or complementary mechanism: eloralintide may be the most interesting. Its weight loss is potentially tirzepatide-level despite not targeting GLP-1, and it could theoretically be paired with an incretin for an amylin-plus-incretin combination.
The important caveat is that there is no completed head-to-head trial showing that retatrutide or eloralintide is superior to tirzepatide. A direct retatrutide-versus-tirzepatide study, TRIUMPH-5, is underway with planned completion in December 2026.
1
1
371
Lilly’s Phase 3 TRIUMPH-1 data put Retatrutide firmly in the spotlight:
• Up to 28.3% average weight loss at 80 weeks
• 45.3% of participants on 12 mg achieved ≥30% weight loss
• Up to 30.3% average loss in the 104-week extension
We summarized the key results in this infographic for researchers tracking the next wave of incretin-based metabolic science.
5
331







